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Abstract:
This semiotic analysis demonstrates how pharmaceutical companies
strategically frame depression within the hotly contested terrain of direct-toconsumer (DTC) advertising. The study tracks regulation of the
pharmaceutical industry, relative to DTC advertising, including recent industry
codes of conduct. Focusing on the antidepressant category, and its three
major brands—Paxil (GlaxoSmithKline), Prozac (Eli Lilly), and Zoloft (Pfizer)—
this comparative study analyzes 7 years of print advertising following
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deregulation in 1997. The authors glean themes from within the advertising
texts, across the drug category and within individual-brand campaigns. The
findings indicate that DTC advertising of antidepressants frames depression
within the biochemical model of causation, privileges benefits over risks, fails
to adequately educate consumers, and frames depression as a female
condition. The authors close with commentary on the potential implications,
with particular focus on the new codes of conduct, and offer suggestions for
future research.
We must ask ourselves: “Are these ads, which we know are costing
billions, properly educating patients or just peddling expensive
products?”
Bill Frist, Senate Majority Leader (Thomaselli, 2005, n.p.)

On August 2, 2005, the Pharmaceutical Research Manufacturers
of America (PhRMA) released its voluntary code of conduct for directto-consumer (DTC) advertising of pharmaceuticals (Appendix A). The
release of these guidelines reflects the pharmaceutical industry’s
efforts to refurbish its tarnished image in the wake of drug recalls and
growing criticism of DTC advertising (Thomaselli, 2005). Yet, for an
industry that spends U.S. $4 billion on its advertising (Thomaselli,
2005), only time will tell if this public relations effort also ultimately
benefits consumers.
Concerns about the best interests of consumers are at the heart
of the heated debate about DTC advertising (Hollon, 2005; Mehta &
Purvis, 2003; “The New Face,” 2005; Paul, Handlin, & Stanton, 2002;
Thomaselli, 2005). Proponents claim that DTC advertising is a powerful
educational tool that increases awareness about health issues, offers
consumers choices in their health care, and encourages medication
compliance (Calfee, 2002; Mehta & Purvis, 2003; “The New Face,”
2005). Opponents charge that DTC advertising is a biased
informational resource that does not adequately explain side effects
and negatively affects the doctor-patient relationship, needlessly
driving up drug costs (Davis, 2000; Hollon, 2005; Holtz, 1998; Lexchin
& Mintzes, 2002; Mehta & Purvis, 2003; “The New Face,” 2005; Paul et
al., 2002).
Previous studies addressing DTC advertising have, in general,
quantitatively examined content and effects (Foote & Etheredge, 2000;
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Hollon, 2005; Holtz, 1998; Kravitz et al., 2005; Lexchin & Mintzes,
2002; Parker & Delene, 1998; Wilkes, Bell, & Kravitz, 2000),
addressed information utility and consumer response (Calfee, 2002;
Huh, Delorme, & Reid, 2004; Mehta & Purvis, 2003; Pinto, Pinto, &
Barber, 1998; Vatjanapukka & Waryszak, 2004; Wilkes et al., 2000),
and analyzed physicians’ attitudes to DTC advertising (Copeland,
2001; Hollon, 2005; Holtz, 1998; IMS Health, 1998; Kravitz et al.,
2005; Sylvain, 2005). However, few studies have provided qualitative,
in-depth analysis of texts as a means of exploring message content
and their implied meanings. Even fewer have focused on a single drug
category— antidepressants.
Overall, the literature on DTC advertising of antidepressants is
limited. Studies by Goldman and Montagne (1986) and Stimson (1975)
address this category; however, their work does not reflect advertising
since deregulation. Hansen and Dawn’s work (1995) addresses
portrayals of females who are elderly, whereas Lõvdahl, Riska, and
Riska (1999) examined this category internationally. Kravitz et al.
(2005) published their groundbreaking study on consumer requests for
antidepressants and the subsequent effects on prescribing rates.
Hollon (2005), Holtz (1998), Kravitz et al. (2005), Mehta and Purvis
(2003), and Paul et al. (2002) implied the need for studies that
address message content within DTC advertising. Hollon (2005) and
Kravitz et al. (2005) suggested the need is particularly salient for drug
categories that are either controversial or address vulnerable
populations, both of which apply to antidepressants. We believe that
the current study, focusing on how DTC print advertising of
antidepressants in Time and Reader’s Digest frames depression, is
significant.

DTC Advertising and Depression
Direct-to-consumer advertising of prescription drugs has been
defined as “any promotional effort by a pharmaceutical firm to present
prescription drug information to the general public through the lay
media” (Kessler & Pines, 1990, p. 2410). However, more recent
literature suggests that DTC advertising generally refers to the
traditional print and television advertising. In today’s marketplaces,
any DTC marketing will necessarily involve multiple layers of
marketing communications. However, for the current study when
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referring to DTC advertising, we refer to traditional advertising and not
promotion.
The pharmaceutical industry utilizes the advertising
effectiveness model, which focuses on exposure, awareness, and
action. This model
holds that (1) advertisement exposure raises consumer
awareness of conditions and treatments; (2) increased
awareness motivates patients to seek medical care and request
drug therapy; and (3) patients’ requests lead, ceteris paribus, to
increased prescribing. Drug manufactures endorse this model to
the tune of $3.2 billion per year. (Kravitz et al., 2005, p. 1999)
It is interesting to note that the United States is the only industrialized
country that utilizes this model because it is the only industrialized
country, other than New Zealand, that permits DTC advertising
(Hollon, 2005).
The American Psychiatric Association (APA, 2000) describes
depression as a clinical course “characterized by one or more Major
Depressive Episodes, without a history of ever having had a manic,
mixed or hypomanic episode, and not due to a general medical
condition or substance-induced mood disorder” (p. 345). Symptoms of
major depression, four of which must be present for a diagnosis,
include changes in appetite, weight or sleep patterns, decreased
energy, feelings of worthlessness or guilt, difficulty concentrating or
making decisions, or recurrent thoughts of death or suicide (APA,
2000).
The APA (2000) stated that treatment options for depression
include psychotherapy (including cognitive and behavioral therapies),
drug therapy, physical exercise, and electro-convulsive therapy. Some
studies suggest that psychotherapy, especially the cognitive approach,
can be highly effective (Gardner, 2001). Psychotherapy is also
considered to be equally effective to drug therapy in cases of mild to
moderate depression (Altshuler, Hendrick, & Burt, 1998). Still other
studies suggest that drug therapy or a combination of drug and
psychotherapy are effective (Altshuler et al., 1998; Carmen, Russo, &
Miller, 1981; Copeland, 2001). The number of patients who were
depressed and were treated with prescription drugs increased from
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37.3% in 1987 to 74.5% in 1997 (Altshuler et al., 1998). At the same
time, the use of psychotherapy declined slightly, despite its recognized
effectiveness (Altshuler et al., 1998; Kotulak, 2002; Vedantam, 2002).
Furthermore, the “percentage of patients who are helped by psychotherapeutic drugs is much lower than commonly claimed” (Valenstein,
1998, p. 165). Gender also appears to complicate diagnosis with
diagnosis being consistently higher among females (Altshuler et al.,
1998; Copeland, 2001; Nadelson & Dickstein, 1998; Weiss &
Lonnquist, 1997), at a rate of three to one to males (Copeland, 2001;
Gardner, 2001).
Depression carries social stigma and is often still considered a
taboo subject. The Mayo Clinic (“Mental Illness and Stigma,” 2005)
describes stigma as a mark of disgrace or shame, which often fuels
inaccurate perceptions of depression. Silenced by social stigma, some
consumers are reticent to discuss depression or seek information.
Stigma and overlapping symptoms can complicate depression
diagnosis. Thus it is fair to suggest that DTC advertising of
antidepressants may target a vulnerable population (Altshuler et al.,
1998; Carmen et al., 1981; Copeland, 2001; Hollon, 2005; Kravitz et
al., 2005), and it is this vulnerability that makes DTC advertising of
antidepressants among the most controversial (Altshuler et al., 1998;
Copeland, 2001; Kravitz et al., 2005).
Medical literature suggests two main theories of causation: the
biochemical theory, also known as the medical model, and the psychosocial theory. The biochemical theory suggests that mental health
disorders arise “from internal causes . . . resulting in impaired social
functioning” (Weiss & Lonnquist, 1997, p. 75). This theory focuses on
irregularities in brain chemistry to conceptualize depression. The
psycho-social theory suggests that stressful personal and social
situations are the explanation for most depression. Stressful situations
may include poverty, marital discord, death of significant others, and
low self-esteem (Freden, 1982). Scholars in psycho-social traditions
point out that many of the depression-inducing life experiences are
associated with demographic factors that include gender (Stoppard,
2000).
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The Pharmaceutical Industry and Advertising
Regulation
Pharmaceutical manufacturers have been advertising for nearly
70 years. The Food and Drug Administration (FDA) implemented
regulation for the pharmaceutical industry in 1938. This early
regulation addressing advertising to physicians is still the standard by
which all drug advertising is judged; however, much has changed
since 1938. First, advertisers are more skilled at research than ever
before, and audience segmentation is now highly sophisticated.
Second, new media have emerged, and advanced technology has
enhanced advertisement production quality. Finally, consumers’
desires for, and access to, information has rapidly expanded.
Nonetheless, only two major changes have occurred in FDA regulations
for the pharmaceutical industry since 1938.
First, in 1985, DTC advertising in print took off when a
government notice stated that “current regulations governing
prescription drug advertising provide sufficient safeguards to protect
consumers” (Holtz, 1998, p. 202). Despite the fact that the FDA
regulations from 1938 focused on advertising to physicians, these
same standards are applied to consumer advertising. Specifically, DTC
print advertisements must include brief summaries to fulfill FDA
requirement (Holtz, 1998). This simply means that advertisers must
list the same information in consumer advertisements that they list in
physician advertisements, with no consideration for the educational
variance between consumers and physicians (Holtz, 1998).
Second, in 1997, the FDA relaxed its restrictions on broadcast
DTC advertising. Since then, antidepressants have become one of the
most heavily advertised drug categories (Rosenthal, Berndt, Donohue,
Frank, & Epstein, 2002). The relaxed restrictions and new focus on
consumers has led to an “explosion” of DTC advertising (Paul et al.,
2002), including huge increases in print advertising budgets (Bell,
Wilkes, & Kravitz, 2000; Paul et al., 2002). The limited range of
advertised drug types suggests that the drugs chosen for intensive
advertising are those that consumers may be most receptive to, not
necessarily those that are in the best interest of overall consumer
health. “Just 20 prescription drugs account for about 60 percent of the
total industry spending on DTCA” (Hollon, 2005, p. 2030).
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Advertising spending across the pharmaceutical industry is
extensive, with some advertising agencies focusing exclusively on this
lucrative category (Courtney, 2003). In 2002, Paxil, handled by
McCann-Erickson Consumer Health, was number 8, and Zoloft, then
handled by Deutsch, was number 20, on the list of 20 top DTC drugs
advertised. Paxil had advertising expenditures of $91,418,000, while
$65,547,00 was spent on Zoloft (“The Tipping Point,” 2003). Pfizer,
Zoloft’s parent company, was the top spending advertiser for DTC
pharmaceuticals, while GlaxoSmithKline, the parent company of Paxil,
was the number 2 spender on DTC advertising (“The Tipping Point,”
2003). In 2001, Lilly’s patent on Prozac expired. Had the Prozac brand
still been on the market in 2003, there is no doubt it too would have
been on the top spenders list.
By 1998, the pharmaceutical industry was spending $1.3 billion
annually on DTC advertising, reflecting “a 20-fold increase over 1991
spending, and more than U.S. companies spent on advertising beer”
(Paul et al., 2002, p. 565). A 134% increase in pharmaceutical sales
between 1997 and 2000 reflects the fruits of this advertising
expenditure (Paul et al., 2002). During this same period, print media
expenditures also ballooned from $573 million to $898 million,
representing a 57.3% increase (Paul et al., 2002). By 2003, $3.2
billion was being spent on DTC advertising (Hollon, 2005; Kravitz et
al., 2005; Paul et al., 2002; Sylvain, 2005). Hollon (2005), in an
editorial in the Journal of the American Medical Association, called this
spending an “uncontrolled experiment” (p. 2030).

Concerns of DTC Advertising
The current study addresses six major concerns of DTC
advertising. First, DTC advertising may not as effectively educate
consumers as the pharmaceutical industry claims (Hollon, 2005; Holtz,
1998; Kravitz et al., 2005; Lexchin & Mintzes, 2002; Paul et al.,
2002). The brief summaries required by the FDA do not address the
educational variances between consumers and physicians (Holtz,
1998), nor does their placement on a separate page enhance the
advertising’s educational value (Hollon, 2005). The separation between
brief summaries and the color image advertisements are far from the
educational tool that the pharmaceutical companies claim (Hollon,
2005; Vatjanapukka & Waryszak, 2004).
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Second, balance between risk and benefit information is lacking.
Weak regulation has allowed the pharmaceutical companies to focus
on the benefits of the drugs and downplay their risks (Hollon, 2005;
Holtz, 1998; Paul et al., 2002; Sylvain, 2005; Vatjanapukka &
Waryszak, 2004). “The standard practice seems to be to list the top
three (risks); however, this may be grossly inadequate” (Holtz, 1998,
p. 215). The lack of clear risk information is one of the strongest
rallying points for opponents of DTC advertising (Davis, 2000; Lexchin
& Mintzes, 2002; Mehta & Purvis, 2003; “The New Face,” 2005).
Third, concerns about the impact of DTC advertising on the
doctor-patient relationship remain (Hollon, 2005; “The New Face,”
2005; Paul et al., 2002; Sylvain, 2005). Direct-to-consumer
advertising adversely affects prescribing rates, which go up “several
fold” when patients request a drug, suggesting that “physicians may
not be the stalwart intermediary that the law assumes” (Kravitz et al.,
2005, p. 2000). Furthermore, a study by Paul et al. (2002) states that
close to 80% of physicians oppose DTC advertising because they feel it
impedes their ability to provide the best possible care to their patients.
Fourth, the costs of prescription drugs continue to rise. The
excessively high cost of advertising has driven up the price of
prescription drugs across all categories (Hollon, 2005; Paul et al.,
2002). Skyrocketing marketing budgets may ultimately affect the
ability of many consumers to afford needed medications (Hollon, 2005;
Holtz, 1998; Kravitz et al., 2005; Paul et al., 2002), as the costs of
prescription drugs have reached an all-time high (Sylvain, 2005;
Vatjanapukka & Waryszak, 2004).
Fifth, the FDA does not have the resources to effectively enforce
its own regulations (Hollon, 2005; Wilkes, 1992), whereas
pharmaceutical companies seem to have ever-deepening pockets. A
study by Wilkes et al. (2000) suggested that 30% of DTC
advertisements potentially violated five or more FDA standards, and
40% did not provide a balanced account of information. The need to
attend to the public outcry over DTC advertising and recent drug
recalls has created a public relations opportunity for PhRMA, which
released the pharmaceutical industry’s new code of conduct. Industry
executives quickly heralded the codes as groundbreaking, whereas
critics assailed the codes as a “softball approach” (Thomaselli, 2005).
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The sixth and final concern is specific to the antidepressant drug
category. It appears that DTC advertising of antidepressants
predominately targets women (Altshuler et al., 1998; Carmen et al.,
1981; Copeland, 2001; Gardner, 2001), promoting stereotypical
assumptions about depression and exacerbating the underdiagnosis of
males and overdiagnosis of females (Copeland, 2001; Gardner, 2001).

Codes of Conduct
These pharmaceutical industry’s codes of conduct (Appendix A),
like other industries’ codes of conduct, are not binding; rather they
may be voluntarily adopted by individual drug manufacturers. “There
are no restrictive features in the 15-point code of conduct” and as a
chief marketing officer stated, “It’s better to self-regulate than to have
somebody else tell you how to conduct your business” (Thomaselli,
2005, n.p.). The codes did not adopt the one-to two-year moratorium
on DTC advertising suggested by many drug industry critics and
supported by the medical community. PhRMA, however, is planning to
establish an office of accountability, to which any signatory company is
bound (Thomaselli, 2005). Congress or the FDA could impose more
regulatory measures, although the underfunding of the FDA (Hollon,
2005) suggests that more regulations are probably not on the horizon.
Thus, it seems that these codes, as a proactive strike by the PhRMA,
appear to be an attempt to head off any future regulations.
Having discussed various aspects of depression, the
pharmaceutical industry, and its regulation, we now set forth the
following three research questions. The over-arching research question
guiding this study is, how has DTC antidepressant advertising framed
depression causation and recovery? Two subquestions are also
explored. First, how are risks and benefits symbolically represented in
the advertisements? Second, what role does gender play, if any, in
how depression is framed within the advertisements?

Theoretical Framework
Semiotic decoding of advertising texts helps contextualize the
framing of messages. Thus, semiotics and frame theory provide
insightful perspectives for examining the symbolism and themes within
DTC advertising. Semiotic theory suggests that signs are selected and
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organized into codes or thematic paradigmatic chains (Fiske, 1990).
Central to semiotics is de Saussure’s (1998) work, which suggests that
all paradigms emerge through cultural and social experiences. Even
the simplest sign has a meaning relevant only to those with knowledge
of the social and cultural context in which it emerges. Signs connoting
meaning are iconic (illustrative forms that are associated with
particular objects), indexical (logical, systemic signs whose
connections are based on shared understandings), and symbolic (signs
that emerge out of cultural and social practices; Peirce, Hartshorne,
Weiss, & Burks, 1994). The signified collides with the signifier creating
a fluid and highly intimate relationship with the reader. The signified
ultimately embodies salient (Entman, 1991) and resonant (Schwartz,
1973) messages, which form the context or thematic frame (Eco,
1984).
Barthes (1977) took us deeper into the social and cultural realm
of semiotic theory. He suggested that signs appear as natural items;
however, the power structure within our cultural and social world is
expressed semiotically through the signification of the sign. Meanings
within signs are postponed; and hence their meaning only emerges
later within the broader social and cultural context in which the texts
circulate. This is particularly insightful for advertising texts, as their
persuasive power is predicated on the authorship of the text being
interactive; that is, the author is removed or “dislocated,” (Barthes,
1977) allowing the reader to take ownership of the text. In the
process, the signifiers and the signified emerge as part of a broader
systemic infrastructure as the authors of the advertising text recede,
becoming archaic (Sturrock, 1979). Texts themselves have no integrity
because they are part of a larger system. Thus, the text becomes an
intermediary between author and reader. The advertising text, as
intermediary, thus becomes part of the cultural world that forms social
reality.
Barthes (1975) offered five codes for semiotic analysis: (a)
hermeneutic orders the sequence of signs; (b) actional defines the
sequence of movement within the text; (c) semic catalogues meanings
within the text; (d) symbolic explores oppositional structures in the
text; and (e) referential connects the text to the extratextual or
historical reality. Barthes actually disparaged the idea of realism.
Rather, he suggested that because of the fluidity of signs, realism is
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fleeting and the “continuity of a text is a deception” (Sturrock, 1979,
p. 75). Thus, intertextuality and history offer the only hope for
grounding the text. Barthes’ semiotic codes form a fluid model and are
thus insightful for advertising analysis, as they suggest that reality is
ever altering and there is no single author. Advertisements are a
conglomeration of multiple internal authors (copywriter, art director,
creative director, planner, client, and more), and the meanings within
advertising texts are dependent on external authorship (readers
decoding the advertisement within their cultural and social
framework). Discourse circulates fluidly around the text, and this
suggests the power of the text to frame or articulate meaning (Bowie,
2001).
At a macro level, frame theory provides a window into the social
and cultural norms of the world in which individuals live, helping them
make meaning of various experiences and events. From a
microperspective, frame theory helps us understand how individuals
make sense of their lived experiences, how individuals sort and
organize the complex stimuli of everyday life (Creed, Langstraat, &
Scully, 2002). Framing can be seen as a process of constructing social
reality in which the producers of mediated texts and the receivers of
those texts interact (Scheufele, 1999). In such light, framing helps
construct “affirmative action” (Gamson, 1992). Social reality is thus
constructed through mediated texts, such as advertisements, and
often takes precedence over lived experiences (Gitlin, 1980).
The framing of social reality becomes possible only when
advertisements have personal resonance (Schwartz, 1973) and
salience (Entman, 1991), all of which leads to selective social reality
(Entman, 1991). To frame is to select some aspects of a perceived
reality and make it more salient in a visual text (Entman, 1991). The
quality of being salient and resonant is what makes the signified
noteworthy and memorable. Furthermore, what is omitted is as
important as what is selected (Entman, 1991). Salience and resonance
are achieved when the messages embedded within the advertising
text, the signified, are consistent with the cultural or social belief
system; thus social reality comes to life through the advertising text.
Selection, salience, and resonance are pivotal to advertising analysis.
Together, semiotics and frame theory allow us to more definitely
access the persuasive intentions of the producers. In this sense,
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
SAGE Publications.

11

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

semiotics and frame analysis are highly compatible for advertising
analysis. Their application has been extended to various social
scientific traditions, including journalism and a wide range of mass
communication studies, and its popularity has grown since its
introduction.

Method
In the current study, a print advertisement is defined as either a
“single page” advertisement or a “spread” (two pages facing one
another). The advertisements analyzed here are image ads, an
industry term that means advertisements that focus on the perceived
benefits of the product rather than the physical features of the product
itself (“product ad”). Furthermore, in pharmaceutical advertisements
there is an additional page listing the brief summary, as required by
the FDA. These brief summaries are not included in the analysis.
Suffice it to say that the brief summaries accompanying each
advertisement are always printed in black and white with
extraordinarily small print, use highly complex medical terminology,
and appear on the page following the image ad. Finally, the brief
summaries never appear on a page directly next to the image ad, so
the image ads and the legally required brief summaries are never
viewed simultaneously.
Six years of print advertisements from Reader’s Digest and Time
were gathered from August 1997 (the month the FDA enacted its
latest deregulation) to August 2003. Reader’s Digest and Time were
selected because of their high circulation. They are the top two
magazines with the highest subscription rate according to MediaMark
(2002). A MediaMark (2002) survey found that Reader’s Digest has a
readership of 43,029,000, whereas Time has a readership of
23,900,000. This same study found that among primary readership
14% of Time’s readers indicate a “considerable interest in advertising,”
whereas 16.8% of Reader’s Digest’s readers indicate a “considerable
interest in advertising.” In addition, Reader’s Digest skews toward
women, whereas Time skews slightly toward men (MediaMark, 2002),
forming a more balanced readership overall. Finally, both have large
audiences, high subscription rates, and significant interest in
advertising among readers, further enhancing the rationale for their
selection.
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The examined print advertisements represent the three major
brands advertised during this time: Prozac, Zoloft, and Paxil (examples
of each brand’s advertisements are included in Appendices B, C, & D).
Twenty-seven advertisements appeared during this time. Six Prozac
advertisements appeared in Time and four in Reader’s Digest. Six
Zoloft advertisements appeared in Time and three in Reader’s Digest.
Six Paxil advertisements appeared in Time and two in Reader’s Digest.
A sampling of advertisements from across 10 randomly selected
magazines (every seventh consumer magazine was pulled from a local
public library shelf for October 1999 and May 2002) confirms that the
same ads ran across multiple media.
It is notable that Prozac’s advertising only ran from August 1997
to April 1998, yet it accounts for the highest placement in these
publications during the entire period of analysis. Being the first brand
to advertise in the DTC venue may account for this high, early media
placement. Zoloft, with the second highest media buy, ran
advertisements from May 2001 to September 2002. Paxil, the leading
seller among antidepressants, has the smallest media buy, with
sporadic placement in 1999, 2000, and 2001, and extensive placement
only in 2002.
Because of space limitations, an in-depth analysis of each
advertisement is impossible. Thus, the current study uses a “purposive
sampling” (Lindlof & Taylor, 2002, p. 120) of ads that exemplify
thematic paradigmatic chains within each brand campaign and
subsequently demonstrate the thematic framing of depression
causation and recovery by each brand. Although selected
advertisements bear strong similarity to others in the campaigns, the
purposive choice represents “their relevance to the research question,
analytical framework, and explanation . . . being developed in the
research” (Schwandt, 2001, p. 233). To that end, headlines and
taglines, visuals, and the placement of copy and visuals (photographs
or illustrations) are discussed in terms of semiotics and frame theory
to illustrate how the thematic framing moves across all the
advertisements within each brand’s campaign.
The following presents study findings based on examining
advertisements for each of the three antidepressants of interest.
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“Welcome back.” Prozac™
Eli Lilly was the first pharmaceutical manufacturer to begin DTC
advertising for antidepressants with its Prozac brand. Lilly was also the
first to cease advertising, most likely in anticipation of its soon-toexpire patent. The Prozac campaign consists of four 2-page spreads
utilizing visual metaphors to construct oppositional codes (Appendix
B). On the left-hand page, a graphically illustrated iconic sign
symbolizes depression, and on the right-hand page the iconic sign
symbolizes recovery. A semic code is created through culturally
relevant seasonal signifiers, setting up a deeper coding system that
becomes extratextual as readers engage with historically bound
cultural understandings of the seasons. The iconic signs on the left are
always weak or incomplete, signifying depression, while the iconic
signs on the right are always strong and fully formed, signifying
recovery. The actional coding signifies that no matter the season one
withers under the strain of depression and blossoms when it is
resolved with Prozac. The iconic signs are strongly supported by the
headlines, which rest beneath them. The font is simple, bolded, and
reverses out of highly color-saturated backgrounds. The oppositional
metaphoric paradigm plays out with the visuals, or iconic signs, and
headlines are grounded in the hermeneutic nature of the seasons.

Color becomes a semic code representing depression with dark
blue, gray, and red, and recovery with yellow, bright blue, and green.
Color also has obvious seasonal signification such as red and green for
Christmas and yellow and blue for spring. The simplicity of the iconic
signs creates a nonthreatening and thus engaging signifier. The use of
saturated colors, a simple typeface, graphic icons, and rhythmic
headlines form a simple, yet highly sophisticated, paradigm of
depression framed by the seasons: recovery is simple with
pharmaceuticals. Cultural connotations are grounded in seasonal
themes with holiday joy, the budding of spring, the warmth of
sunshine, and the security of togetherness. These recovery
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connotations are rooted in the morphed visuals, which become
signified by the presence of the sunny Prozac logo, whose o is a sun,
the semic code for recovery. The actional codes, which suggest the
sequence of events within these advertisements, lead directly to the
logo, which in turn links recovery unambiguously to the Prozac brand
name and thus creates an unmistakable referential code for
biochemical recovery.
A rhythmic pattern of copy flows across the entire campaign.
The copy stresses the oppositional paradigmatic chains grounded in
the symbolic codes. The headlines, “Depression
hurts/shatters/isolates/saddens,” link seamlessly to the iconic visuals.
The tagline, “Welcome back,” reinforces the signified actional code that
recovery is easily available with Prozac. The words of the tagline
rhythmically repeat the messages in the headlines, thus reinforcing the
overall extratextual framing that depression can be simply erased with
pharmaceuticals. The transition lines of the body copy, “Depression is .
. . /It’s a real illness with real causes ...” form semic codes linked to
the iconic visual signifiers above each headline. Early in the body copy,
the semic construction of biochemical causes begins. “Some people
think you can just will yourself out of depression. That’s not true.” A
simplistic explanation of depression follows, with a listing of principal
symptoms, and this leads to a biochemical actional code or call to
action with the copy line, “The medicine doctors now prescribe most
often is Prozac™.” Minimal disclaimers and a few “mild side effects”
are then listed within the image ad itself. The only reference to
nonpharmaceutical treatment options, a single line of copy (of nearly
50 lines), suggests the possibility of psychotherapy, but only after one
has begun taking Prozac. The body copy closes with actional codes
framed

This semiotic analysis of these advertisements helps illuminate
how seasonal social reality is constructed and utilized to frame
depression causation as conversely natural and out of an individual’s
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
SAGE Publications.

15

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

control. This biological paradigm takes precedence over lived
experiences (Gitlin, 1980), and in the process, salient social and
cultural signifiers become the referential codes for depression. As
salience frames social reality (Entman, 1991), the seasonal signifiers
set up the framing of pharmaceuticals as the only viable treatment
option for depression. With seasonal causation for depression framed
as natural, and thus biological, the framing of depression recovery
rests equally naturally in pharmaceuticals. Using resonant everyday
life seasonal experiences (Schwartz, 1973), Lilly frames Prozac as the
biochemical solution to a natural problem rooted in the consumer’s
biological nature and simply triggered by seasonal experiences; thus
constructed reality supercedes lived experiences. Ultimately,
oppositional codes suggest a subtle but rather ironic framing, which
signify that seasonal celebrations are simply moments in time when
individuals’ biological depression emerges.

“When you know more about what’s wrong, you
can help make it right.” Zoloft™
Pfizer began running advertisements for its Zoloft brand in early
2001 and continued through late 2002. The campaign consisted of four
advertisements (Appendix C). Those in Time were single-page
advertisements, and those in Reader’s Digest were spreads. The
content does not change; however, the layout shifts slightly to
accommodate the differing formats. This campaign, like Prozac’s,
featured illustrated iconic signs along with the copy. The Zoloft
campaign adds an additional illustrative icon, a medicalized diagram
whose semic code “demonstrates” the chemical reactions of Zoloft
within the brain thus expanding the paradigmatic chain leading directly
to the biochemical model of depression causation and treatment. Each
advertisement is executed in black and white, which connotes the
seriousness of the illness, yet the simplicity of the drawings of the
Zoloft icon (or egg, as it is sometimes referred to) and the “medical
diagram” oppositionally imply simplicity. The ovalesque shape of the
Zoloft icon, signifying a pill, referentially enhances the medicalization
of depression.
Human features ascribed to the Zoloft icon, such as eyes, hair,
and mouth, come to signify depression in its human form. The human
references become part of the extratextual experience of depression,
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thus allowing semic codes to be placed on the icon. A contrasting spike
in the line across the top of the icon signifies a tuft of hair. Other lines
and circles combine to connote eyes. Subtle curving lines graphically
signify tears, surprise, or anxiety. A simple, curved stroke near the
bottom of the icon signifies a mouth, often downturned in a frown or
wrinkle, connoting sadness. A drop shadow beneath the Zoloft icon
signifies groundedness and movement, further signifying the human
qualities ascribed to the inanimate Zoloft icon. Smooth motion lines
around the Zoloft icon connote running, and when combined with
squiggled “facial” lines connote fear. Wiggly motion lines connote
shaking and thus are referential codes signifying panic. The absence of
motion lines signifies isolation, building referential codes for
depression. Furthermore, by utilizing the illustrative inanimate form to
create the Zoloft icon, oppositional symbolic codes emerge. These
optional codes allow depression to be at once human and chemical.
Creating referential signs of humanness, while not showing a human,
serves to reduce the stigma of depression. Thus the tagline, “When
you know more about what’s wrong, you can help make it right,”™
becomes individualized and acceptable. With stigma reduced, the you
becomes an individual abstraction, and the symptoms of depression
become at once less threatening, more manageable, and personal.
You, now signified as detached from the depression, codifies the
medical model as the manageable solution to “your” problem.
With the stigma reduced, the actional codes lead directly to the
medicalized diagram, a highly simplistic drawing connoting “chemical
imbalance” and the change that occurs “with Zoloft.” These captions
define the semic code within the diagram of nerve endings and brain
chemicals, signified by crudely drawn circles or dots. Without Zoloft,
there are few dots. However, the subhead, resting beneath the
medicalized diagram states, “Prescription Zoloft works to correct this
imbalance.” Thus, the dots signifying Zoloft become the extratextual
referential signs of recovery. Symbolically, the power of recovery is
grounded in the chemical reaction—the dots that signify Zoloft.
Ultimately, both illustrated icons (the Zoloft icon and the medicalized
diagram) come to signify that with Zoloft “ . . . you can make it right.”
A multiple series of bolded headlines codify depression
symptoms, leading to a highly simplistic description of depression that
supports the coding within the medicalized diagram.
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
SAGE Publications.

17

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Headlines
“You know why you feel the weight of sadness.”
“You may feel exhausted, hopeless, and anxious.”
“Things just don’t feel like they used to.”
The first headline begins the hermeneutic code circularly linking
the headline to the visual sign of the Zoloft icon. In the case of feeling
“the weight of sadness,” the Zoloft icon is under a “heavy” rain cloud.
The shadow beneath it, along with the cloud, rain, and tears form
semic codes for weighty sadness. Midway through the body copy
actional codes for the medical model are employed with “Only your
doctor can diagnose depression,” which implies that only a doctor can
cure depression, which reinforces the detachment codified by the
inanimate Zoloft icon. Brief side effects follow, and a final call to
action, “Talk to your doctor about Zoloft, the #1 prescribed brand of
its kind. Call . . . for more information,” sets up actional codes. As with
the Prozac advertisements, the cursory listing of mild side effects has
the intended effect of framing the side effects as minor and thus
negating the “brief summary” on the following page.
Gitlin’s (1980) perspective that social reality takes precedence
over other experiences frames these advertisements. The social
realities framed by the Zoloft icon, be they “weighty” sadness under a
“heavy” cloud or the “fearsome” grip of anxiety under the “shadow” of
a looming hand, are known consumer realities. They have salience
(Entman, 1991) and cultural resonance (Schwartz, 1973). The graphic
framing of depression as chemically bound, framed within the
biochemical model, offers readers the opportunity to “select”
information that on the surface appears educational. Yet the selective
framing (Entman, 1991) of depression is limited and unmistakably
biochemical. The oppositional construction of the detached Zoloft icon,
along with the use of the personal pronoun you, referentially
establishes personal resonance (Schwartz, 1973), whereas the
symbolically informational medicalized diagram works to frame a
highly complex illness simplistically. These simple, friendly, and
approachable black-and-white illustrated advertisements frame and
organize depression as an easily understood biochemical imbalance.
Everyday life, so simply organized (Creed et al., 2002), frames the
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problem as simply resolved “with Zoloft.” For “When you know more
about what’s wrong, you can help make it right,” with “prescription
Zoloft.”

“Your Life Is Waiting.” Paxil™
Direct-to-consumer advertising of today’s number-1 selling
antidepressant, Paxil, began appearing in print in 1999 and continues
to date. The strategic focus across the campaign is anxiety (Appendix
D). Unlike Prozac and Zoloft advertisements, the visuals in all Paxil
advertisements employ models as indexical signs. As with Prozac and
Zoloft, oppositional themes frame the campaign. Unlike Prozac and
Zoloft, whose campaigns had highly consistent imagery and copy, the
Paxil campaign had wider variation in imagery and layout. Yet, like
Prozac and Zoloft, the Paxil campaign had consistency in copy content.
Thus, multiple ads are analyzed.
The campaign utilizes symptoms, as copy, to create repetitive
subheads that visually form a symbolic wall of words, literally
separating the anxious and nonanxious models. Through this
separation, isolation becomes a symbolic oppositional code for anxiety.
The female models are always signified as anxious and separated from
the male models who are nonanxious. The headline, “What’s standing
between you and your life?” forms an actional code paradigmatically
linking anxiety directly on the female model. Beneath this main visual
is a small close-up photograph of the female model embracing a young
male model. The sign formed by embracing “mother” and “son” comes
to signify recovery and is strategically placed between signifiers of
isolation and the logo signifying chemical recovery. Actional codes
drive the copy. “A chemical imbalance could be to blame. And life can
feel difficult ALL DAY. That’s why you need relief ALL DAY.” The overall
hermeneutic code begins with the headline, “What’s standing between
you and your life?” and ends with the Paxil logo and tagline, “Your life
is waiting!”
Another advertisement uses semic codes of floating symptoms
as copy to signify the anxiety of isolation, much like the wall of words
from the previous advertisements. This signification is heightened by
the oppositional symbolic codes of a blurred crowd surrounding the
crisp image of an anxious female model. A split headline, “Millions
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suffer from chronic anxiety,” literally cuts through the model’s body,
suggesting referential codes to the broader world and her isolation
from it. The second part of the split headline, “Millions could be helped
by Paxil,” is placed beneath her body on a calming yellow background,
creating semic codes of groundedness all located in the Paxil brand.
The hermeneutic code definitively orders the sequence of anxiety,
depression, and recovery within the biochemical model.
In another advertisement, semic coding is apparent in the
choice of the color blue, which suggests the extratextual context of
“feeling blue.” Following the same thematic strategy as demonstrated
previously, before-and-after visuals signify the biochemical model. The
advertisement begins with a questioning headline, “Has social anxiety
put your life on hold?” The use of questioning headlines engages the
reader in actional codes, encouraging movement into the body of the
ad, where the subhead, “You are not alone,” signifies that the answer
lies with Paxil. An iconic wall continues to be utilized symbolically,
representing isolation. This time, models lean against a wall holding
their heads in their hands. One advertisement features a male and the
other a female. Significantly, the male is cropped tightly; at a glance
gender signification is muted. The female is cropped more broadly
making the signification of femininity exceedingly clear. Visual
signification of depression is paradigmatically linked with the subhead
“put your life on hold.” Symptoms are listed within the body copy and
lead to bolded copy stating that “Paxil is the only medication . . .
approved by the FDA.” The FDA, signifying an authoritative education
code, links into the referential code for the biochemical model. When
the biochemical model is established, signification of recovery is
seamlessly linked to Paxil.
The logo and a “survey” are contained within a series of broken
lines signifying a coupon. The use of the boxed coupon style signifies
containment and thus the power of Paxil to contain anxiety. Actional
codes such as boxes to check, a circled logo, and the broken lines
forming the coupon itself encourage engagement with the text and
thus the brand. “You may want to cut this out and show it to your
doctor” implies a direct reference to the doctor-patient relationship.
Across the Paxil campaign, 74% of the models are female,
whereas 26% are male. Females are signified as depressed 96% of the
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
SAGE Publications.

20

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

time whereas males are codified as depressed only 13%. By contrast,
no more than 5% of all advertisements are males signified as
depressed. A model was judged to be depressed by its overall visual
representation (sad face, head in hands, etc.), its association with the
copy elements referring to the symptoms of depression (e.g.,
sleeplessness, loneliness, etc.), and references to visual and textual
elements that represent happiness (e.g., smile, hugging a child, etc.).
The resulting semic codes signify males as stable and supportive while
signifying females as anxious and unstable. Despite the strikingly
gendered visual referent system, the copy remains gender neutral.
Visual signs within the text have more salience over copy, however
(Entman, 1991), and constructed social reality takes precedence over
lived experiences, thus the paradigmatic effect supports the overall
gender bias of females as depressed.
The Paxil campaign quite literally, through a systemic
infrastructure (Sturrock, 1979) of walls and boxes, frames depression
and anxiety as biochemical problems, easily resolved with Paxil.
Oppositional codes grounded in isolating distance, using before-andafter visual images, suggest the power of the visual text (Entman,
1991). Grounded in salient selectivity (Entman, 1991), codes of
isolation become salient triggers, and the questioning headlines
heighten anxiety. Referential codes from the boxed survey, to the
authority signified within the FDA, to significations of recovery in an
embrace, construct affirmative action (Gamson, 1992) and frame the
solution to anxiety and depression as biochemical. With 96% of all
images signifying depression as a feminine problem, by using female
models, selective salience (Entman, 1991) is powerfully articulated.
The campaign frames anxiety as grounded in everyday life social
experiences (Gitlin, 1980), yet the coded text signifies it as biologically
female. As visual texts always dominate (Entman, 1991), the
feminization of depression by GlaxoSmithKline and its number-1
selling antidepressant, Paxil, is unmistakable.

Conclusions
Returning to the overarching question of how DTC advertising of
antidepressants frames depression, causation, and recovery, the
current study strongly articulates a biochemical framing in which
selective and salient codes (Entman, 1991) dominate the framing of
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depression. On the surface, this comes as no surprise considering the
product category is pharmaceuticals. Furthermore, we do not dismiss
the possibility that depression has a biological component. However,
the larger concern is about how narrowly causation is framed and how
cultural and social practices are used to symbolize (Peirce et al.,
1994); not actual practices but rather distorted frames of social reality
(Gitlin, 1980). Certainly, framing causation and recovery as naturally
biochemical forms a very compelling argument for utilizing drug
therapy. At the same time, though, it marginalizes the psycho-social
causes for depression, thus minimizing the potential for a broader
discussion about depression’s impact on society or conversely the
social causes of depression. Narrowing the frame to biochemical is the
true point of danger because in doing so reality becomes fleeting
(Barthes, 1975) and individuals living in situations that are inherently
stressful, anxiety producing, and/or depressing are marginalized. Thus
selective social reality (Entman, 1991) becomes finite, making
individuals responsibility loom large.
Using social conditions and lived experiences as hooks or
triggers, every advertisement analyzed constructs as resonant
(Schwartz, 1974) and salient social reality that takes precedence over
all lived experiences (Entman, 1991). When resonance is established,
the advertising strategically shifts the focus from broader social
experiences and conditions to the individual, while social conditions
and causation recede. Reflecting Entman’s (1991) proposition that
omissions are highly salient, the problem of depression is placed
squarely on the individual and her or his biology. Contrarily,
salvation—constructed through paradigmatic chains (Fiske, 1990)—is
linked to an individualized solution: pharmaceuticals. Thus, as texts
take precedence over reality, the truly salient question is not how
antidepressants (or other drugs) are advertised to consumers but
whether we should be advertising pharmaceuticals to consumers at all.
Unfortunately, this debate is not on the table. Successful DTC
advertising of antidepressants is all about the bottom line,
necessitating an inextricable link to biology— not serious consumer
education, balanced risk, and benefit information; protection of the
doctor-patient relationship; affordable drugs available to all; or
concern for gender equity. DTC advertising of antidepressants is, of
course, all business, and so are PhRMA’s newly proposed codes of
conduct.
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The first subresearch question addresses how risks and benefits
are symbolically framed in DTC advertisements of antidepressants. We
suggest that risks are appallingly underprivileged. As Entman (1991)
suggested, omission has high salience. Omissions, along with the fluid
discourse (Bowie, 2001), frame recovery as biochemical signified by
pharmaceuticals. The power of this framing affirms that benefits are
highly privileged. To that end, antidepressants are framed as a quick
fix to what is truly a larger and more complex problem. Considering
that the product category is pharmaceuticals and the fact that the use
of drugs is predicated on serious health conditions, minimizing risks
seems at the least problematic and at the worst dangerous and
unethical. With risks symbolically minimized within these image
advertisements, and virtually lost in the complex language and
obscure placement of the brief summaries, the health care information
provided through DTC advertising is seriously compromised because
the “continuity of a text is a deception” (Sturrock, 1979, p. 75). The
claims that DTC advertising is educational are erroneous on this point
alone. Furthermore, these advertisements selling consumers a quick
fix, and not too subtly promoting self-diagnosis, confound the doctorpatient relationship. Without an unvarnished and accessible
understanding of the overall risks and benefits and treatment options,
consumers are not well served. When it comes to risk information and
treatment options, especially for at-risk individuals, the standards
must be raised and the doctor-patient relationship must be protected.
The lived experiences of patients must supersede constructed social
reality.
The second subresearch question explores how gender plays a
role in the framing of depression within DTC advertising of
antidepressants. The number-1 selling brand, Paxil, clearly and
saliently frames depression as an overwhelmingly female disease.
Within the Prozac and Zoloft campaigns, gender construction is subtle,
with neutralized semic codes of gender intentionally embedded in
iconic visuals. The gender neutrality within semiotic content may well
be a strategic tactic to engage men and women, with the intent of
engaging women through the men in their lives or tapping into
women’s greater propensity to seek medical care. However, this is
purely speculative. It is the intersection of the biochemical model with
salient semic codes for femininity that is most disturbing. This
combination has deep historical, referential salience, and thus the
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power to perpetuate the stereotype of females as biologically
depressive obscures the psycho-social factors that significantly affect
females’ lives— from poverty to abuse to discrimination. Finally, the
consequences of framing depression as predominately female will only
perpetuate the overdiagnosis among females and underdiagnosis
among males.
Individualized quick fixes, rooted in the biochemical paradigm,
negate the larger and significantly more pressing question of the
impact of depression and its root causes for society at large. This
paradigm privileges constructed reality over lived experiences (Gitlin,
1980). Selective omissions (Entman, 1991) seem to be the rule, rather
than the exception, and a systemic infrastructure (Sturrock, 1979)
promotes deception. Limited educational value, an abhorrent
minimization of risks, intrusion on the long-privileged doctor-patient
relationship, rising drug costs, limited regulation, and the perpetuation
of gendered stereotypes risk leaving consumers more depressed and
discouraged than ever before.
Advertising of pharmaceuticals may not be new; however, the
intensity of DTC advertising, particularly antidepressants, should be a
red flag to all. The salience of their construction and the power of their
omissions (Entman, 1991) should spur us on to critically analyze these
deceptive texts. With this in mind, we suggest that the voices of
consumers need to be heard more often in the literature, as they are
the ultimate interpreters of DTC advertising. In addition, no current
study gives voice to the individuals who create these advertisements,
and as Barthes suggested, one cannot study texts “in isolation from
their mode of production” (as cited in Sturrock, 1979, p. 64).
Furthermore, a comparative study of advertisements produced before
and after implementation of the new PhRMA codes of conduct could
offer insights into the impact of these new codes. The words of
Senator Frist call us to seriously consider whether these
advertisements are “‘properly educating patients or just peddling
expensive products’” (Thomaselli, 2005, n.p.).
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Appendix A
Pharmaceutical Industry Issues DTC Ad Guidelines
Softball Approach Rejects Calls for Restrictions or
Moratorium
Text of PhRMA Principles
PhRMA Guiding Principles on Direct to Consumer Advertisements About
Prescription Medicines
To express the commitment of PhRMA members to deliver DTC
communications that serve as valuable contributors to public health,
PhRMA has established the following voluntary guiding principles.
1.

These Principles are premised on the recognition that DTC
advertising of prescription medicines can benefit the public
health by increasing awareness about diseases, educating
patients about treatment options, motivating patients to contact
their physicians and engage in a dialogue about health
concerns, increasing the likelihood that patients will receive
appropriate care for conditions that are frequently underdiagnosed and under-treated, and encouraging compliance with
prescription drug treatment regimens.

2.

In accordance with FDA regulations, all DTC information should
be accurate and not misleading, should make claims only when
supported by substantial evidence, should reflect balance
between risks and benefits, and should be consistent with FDA
approved labeling.

3.

DTC television and print advertising which is designed to market
a prescription drug should also be designed to responsibly
educate the consumer about that medicine and, where
appropriate, the condition for which it may be prescribed.

4.

DTC television and print advertising of prescription drugs should
clearly indicate that the medicine is a prescription drug to
distinguish such advertising from other advertising for
nonprescription products.
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5.

DTC television and print advertising should foster responsible
communications between patients and health care professionals
to help patients achieve better health and a more complete
appreciation of both the health benefits and the known risks
associated with the medicine being advertised.

6.

In order to foster responsible communication between patients
and health care professionals, companies should spend an
appropriate amount of time to educate health professionals about
a new medicine or a new therapeutic indication before
commencing the first DTC advertising campaign. In determining
what constitutes an appropriate time, companies should take into
account the relative importance of informing patients of the
availability of a new medicine, the complexity of the risk-benefit
profile of that new medicine and health care professionals’
knowledge of the condition being treated. Companies should
continue to educate health care professionals as additional valid
information about a new medicine is obtained from all reliable
sources.

7.

Working with the FDA, companies should continue to responsibly
alter or discontinue a DTC advertising campaign should new and
reliable information indicate a serious previously unknown safety
risk.

8.

Companies should submit all new DTC television advertisements
to the FDA before releasing these advertisements for broadcast.

9.

DTC television and print advertising should include information
about the availability of other options such as diet and lifestyle
changes where appropriate for the advertised condition.

10.

DTC television advertising that identifies a product by name
should clearly state the health conditions for which the medicine
is approved and the major risks associated with the medicine
being advertised.

11.

DTC television and print advertising should be designed to
achieve a balanced presentation of both the benefits and the risks
associated with the advertised prescription medicine. Specifically,
risks and safety information in DTC television advertising should
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be presented in clear, understandable language, without
distraction from the content, and in a manner that supports the
responsible dialogue between patients and health care
professionals.
12.

All DTC advertising should respect the seriousness of the health
conditions and the medicine being advertised.

13.

In terms of content and placement, DTC television and print
advertisements should be targeted to avoid audiences that are
not age appropriate for the messages involved.

14.

Companies are encouraged to promote health and disease
awareness as part of their DTC advertising.

15.

Companies are encouraged to include information in all DTC
advertising, where feasible, about help for the uninsured and
underinsured.

Source: Thomaselli (2005).
Note: DTC = direct-to-consumer; PhRMA = Pharmaceutical Research Manufacturers of
America.
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Appendix B
Prozac Advertisements
Some images have been removed
from this version of the article due to
third-party copyright restrictions.
Please see definitive published
version to view image:
http://dx.doi.org/10.1177/01968599
05285315

Appendix C
Zoloft Advertisement
Some images have been removed
from this version of the article due to
third-party copyright restrictions.
Please see definitive published
version to view image:
http://dx.doi.org/10.1177/01968599
05285315

Appendix D
Paxil Advertisements
Some images have been removed
from this version of the article due to
third-party copyright restrictions.
Please see definitive published
version to view image:
http://dx.doi.org/10.1177/01968599
05285315
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Appendix D (continued)

Some images have been removed
from this version of the article due to
third-party copyright restrictions.
Please see definitive published
version to view image:
http://dx.doi.org/10.1177/01968599
05285315
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